Sign inJoin waitlistJoin the waitlist

EB

Elizabeth Brem

Chair of a Study of Patients Aged 75 and Older with a New Diagnosis of Diffuse Large B-Cell Lymphoma · National Clinical Trials Network

Credentials: · · · · · ·

History

University of California
Present
University of California
Present

Hematology and Medical Oncology
Beth Israel Deaconess Medical Center
2013–2016
Internal Medicine
Beth Israel Deaconess Medical Center
2010–2013
Hospice and Palliative Medicine
University at Buffalo School of Medicine
2009–2010
University at Buffalo School of Medicine and Biomedical Sciences
2006–2010

Research

Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas
British Journal of Haematology · 2011 · First of 18 authors · 49 citations
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas
Blood · 2019 · 49 citations
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
Blood Advances · 2023 · 42 citations

Alex Koyfman
5 papers · 2 as a resident
Piyanuch Kongtim
4 papers
Stefan Ciurea
4 papers
BL
Brit Long
3 papers
Edward Kuan
3 papers
Joseph Tuscano
3 papers
Kevin Shieh
3 papers · 3 as a fellow
SR
Sherif Rezk
3 papers
SO
Susan O'Brien
3 papers
AL
Anthony Letai
2 papers
AA
Arash Abiri
2 papers
AG
Ashley Gamayo
2 papers

Clinical trials

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
Principal investigator · Active not recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2021–2027
Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia
Principal investigator · Completed · Phase 1
University of California, Irvine
2020–2025
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2027
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032